Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FPF 1070

Drug Profile

FPF 1070

Alternative Names: Cerebrolysin

Latest Information Update: 20 Jan 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ebewe Neuro Pharma
  • Developer EVER Neuro Pharma
  • Class Nootropics; Peptides; Tissue extracts
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Stroke
  • Discontinued Brain injuries

Most Recent Events

  • 10 Nov 2016 Launched for Stroke in Poland (IV)
  • 29 Dec 2010 EVER Neuro Pharma completes a phase-II trial in Stroke in Poland (EudraCT2007-000870-21)
  • 18 Aug 2009 Discontinued - Phase-II for Brain injuries in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top